Literature DB >> 29943229

Is Braak staging valid for all types of Parkinson's disease?

Kurt A Jellinger1.   

Abstract

Braak et al. proposed that cases with Lewy pathology in the peripheral nervous sytem, spinal cord and brain stem are prodromal Parkinson's disease (PD), suggesting a hypothesized progression of PD pathology. However, the putative potential of peripheral α-synuclein to promote brain pathology has been questioned recently. The Braak staging is a matter of vigorous debate, since < 100% of cases with Lewy pathology fitting the proposed PD staging scheme; however, most studies assessing typical PD cases show that the vast majority (80-100%) fit the Braak staging scheme. Incidental Lewy body disease and PD can show Lewy pathology in substantia nigra or other brain areas without involvement of dorsal motor nucleus of the vagus nerve. The Braak staging system is valid for PD patients with young onset, long duration with motor symptoms, but not for others, e.g., late onset and rapid course PD. The validity of Braak staging and its relationship to various subtypes of PD warrants further studies.

Entities:  

Keywords:  Braak staging; Guidelines; Lewy body disease; Lewy pathology; Parkinson’s disease

Mesh:

Year:  2018        PMID: 29943229     DOI: 10.1007/s00702-018-1898-9

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  95 in total

1.  The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson's disease.

Authors:  J Attems; K A Jellinger
Journal:  Neuropathol Appl Neurobiol       Date:  2008-02-13       Impact factor: 8.090

Review 2.  Invited Article: Nervous system pathology in sporadic Parkinson disease.

Authors:  Heiko Braak; Kelly Del Tredici
Journal:  Neurology       Date:  2008-05-13       Impact factor: 9.910

3.  α-Synuclein strains cause distinct synucleinopathies after local and systemic administration.

Authors:  W Peelaerts; L Bousset; A Van der Perren; A Moskalyuk; R Pulizzi; M Giugliano; C Van den Haute; R Melki; V Baekelandt
Journal:  Nature       Date:  2015-06-10       Impact factor: 49.962

4.  Cognitive status correlates with neuropathologic stage in Parkinson disease.

Authors:  H Braak; U Rüb; E N H Jansen Steur; K Del Tredici; R A I de Vos
Journal:  Neurology       Date:  2005-04-26       Impact factor: 9.910

5.  Lewy pathology is not the first sign of degeneration in vulnerable neurons in Parkinson disease.

Authors:  Joshua M Milber; Joseph V Noorigian; James F Morley; Helen Petrovitch; Lon White; G Webster Ross; John E Duda
Journal:  Neurology       Date:  2012-11-14       Impact factor: 9.910

6.  Ageing and Parkinson's disease: substantia nigra regional selectivity.

Authors:  J M Fearnley; A J Lees
Journal:  Brain       Date:  1991-10       Impact factor: 13.501

7.  In dementia with Lewy bodies, Braak stage determines phenotype, not Lewy body distribution.

Authors:  D Weisman; M Cho; C Taylor; A Adame; L J Thal; L A Hansen
Journal:  Neurology       Date:  2007-07-24       Impact factor: 9.910

8.  Empiric refinement of the pathologic assessment of Lewy-related pathology in the dementia patient.

Authors:  James B Leverenz; Ronald Hamilton; Debby W Tsuang; Aimee Schantz; Darcy Vavrek; Eric B Larson; Walter A Kukull; Oscar Lopez; Douglas Galasko; Eliezer Masliah; Jeffrey Kaye; Randall Woltjer; Christopher Clark; John Q Trojanowski; Thomas J Montine
Journal:  Brain Pathol       Date:  2008-01-29       Impact factor: 6.508

Review 9.  Evidence for dopaminergic axonal degeneration as an early pathological process in Parkinson's disease.

Authors:  Gerard W O'Keeffe; Aideen M Sullivan
Journal:  Parkinsonism Relat Disord       Date:  2018-06-19       Impact factor: 4.891

Review 10.  Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium.

Authors:  Ian G McKeith; Bradley F Boeve; Dennis W Dickson; Glenda Halliday; John-Paul Taylor; Daniel Weintraub; Dag Aarsland; James Galvin; Johannes Attems; Clive G Ballard; Ashley Bayston; Thomas G Beach; Frédéric Blanc; Nicolaas Bohnen; Laura Bonanni; Jose Bras; Patrik Brundin; David Burn; Alice Chen-Plotkin; John E Duda; Omar El-Agnaf; Howard Feldman; Tanis J Ferman; Dominic Ffytche; Hiroshige Fujishiro; Douglas Galasko; Jennifer G Goldman; Stephen N Gomperts; Neill R Graff-Radford; Lawrence S Honig; Alex Iranzo; Kejal Kantarci; Daniel Kaufer; Walter Kukull; Virginia M Y Lee; James B Leverenz; Simon Lewis; Carol Lippa; Angela Lunde; Mario Masellis; Eliezer Masliah; Pamela McLean; Brit Mollenhauer; Thomas J Montine; Emilio Moreno; Etsuro Mori; Melissa Murray; John T O'Brien; Sotoshi Orimo; Ronald B Postuma; Shankar Ramaswamy; Owen A Ross; David P Salmon; Andrew Singleton; Angela Taylor; Alan Thomas; Pietro Tiraboschi; Jon B Toledo; John Q Trojanowski; Debby Tsuang; Zuzana Walker; Masahito Yamada; Kenji Kosaka
Journal:  Neurology       Date:  2017-06-07       Impact factor: 9.910

View more
  26 in total

Review 1.  Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update. II. Hyperkinetic disorders.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2019-06-24       Impact factor: 3.575

Review 2.  Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update-I. Hypokinetic-rigid movement disorders.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2019-06-18       Impact factor: 3.575

Review 3.  α-Synuclein in Parkinson's disease: causal or bystander?

Authors:  Peter Riederer; Daniela Berg; Nicolas Casadei; Fubo Cheng; Joseph Classen; Christian Dresel; Wolfgang Jost; Rejko Krüger; Thomas Müller; Heinz Reichmann; Olaf Rieß; Alexander Storch; Sabrina Strobel; Thilo van Eimeren; Hans-Ullrich Völker; Jürgen Winkler; Konstanze F Winklhofer; Ullrich Wüllner; Friederike Zunke; Camelia-Maria Monoranu
Journal:  J Neural Transm (Vienna)       Date:  2019-06-25       Impact factor: 3.575

Review 4.  Depression in Patients with Parkinson's Disease: Current Understanding of its Neurobiology and Implications for Treatment.

Authors:  Stéphane Prange; Hélène Klinger; Chloé Laurencin; Teodor Danaila; Stéphane Thobois
Journal:  Drugs Aging       Date:  2022-06-16       Impact factor: 4.271

Review 5.  Prodromal Parkinson disease subtypes - key to understanding heterogeneity.

Authors:  Daniela Berg; Per Borghammer; Seyed-Mohammad Fereshtehnejad; Sebastian Heinzel; Jacob Horsager; Eva Schaeffer; Ronald B Postuma
Journal:  Nat Rev Neurol       Date:  2021-04-20       Impact factor: 42.937

Review 6.  Perspective: Treatment for Disease Modification in Chronic Neurodegeneration.

Authors:  Thomas Müller; Bernhard Klaus Mueller; Peter Riederer
Journal:  Cells       Date:  2021-04-12       Impact factor: 6.600

Review 7.  Possible Link between SARS-CoV-2 Infection and Parkinson's Disease: The Role of Toll-Like Receptor 4.

Authors:  Carmela Conte
Journal:  Int J Mol Sci       Date:  2021-07-01       Impact factor: 5.923

Review 8.  Alpha-Synuclein as a Biomarker of Parkinson's Disease: Good, but Not Good Enough.

Authors:  Upasana Ganguly; Sukhpal Singh; Soumya Pal; Suvarna Prasad; Bimal K Agrawal; Reena V Saini; Sasanka Chakrabarti
Journal:  Front Aging Neurosci       Date:  2021-07-08       Impact factor: 5.750

Review 9.  Recent Insights into the Interplay of Alpha-Synuclein and Sphingolipid Signaling in Parkinson's Disease.

Authors:  Joanna A Motyl; Joanna B Strosznajder; Agnieszka Wencel; Robert P Strosznajder
Journal:  Int J Mol Sci       Date:  2021-06-11       Impact factor: 5.923

Review 10.  View Point: Disease Modification and Cell Secretome Based Approaches in Parkinson's Disease: Are We on the Right Track?

Authors:  Thomas Müller
Journal:  Biologics       Date:  2021-07-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.